

THOMSON
DELPHION

RESEARCH

SERVICES

INSIDE DELPHION

Log Out | Work File | My Alerts | My Account | My Profile | My Settings | My Tools | My Reports | My Documents | My Favorites | My History | My Recent | My Watched | My Subscribed | My Shared | My Groups | My Roles | My Permissions | My Settings | My Profile | My Account | My Alerts | My Work File | My Recent | My Watched | My Subscribed | My Shared | My Groups | My Roles | My Permissions

The Delphion Integrated View

Get Now: [More choices...](#)Tools: Add to Work File: [Create new Wo](#)View: [Expand Details](#) | [INPADOC](#) | Jump to: [Top](#)[Email](#)**Title:** EP1293569A2: Full-length cDNAs**Country:** EP European Patent Office (EPO)**Kind:** A2 Publ. of Application without search report¹**Inventor:** Isogai, Takao;
Sugiyama, Tomoyasu;
Otsuki, Tetsuji;
Wakamatsu, Ai;
Sato, Hiroyuki;
Ishii, Shizuko;
Yamamoto, Jun-ichi;
Isono, Yuuko;
Hio, Yuri;
Otsuka, Kaoru;
Nagai, Keiichi;
Irie, Ryotaro;
Tamechika, Ichiro;
Seki, Naohiko;
Yoshikawa, Tsutomu;
Otsuka, Motoyuki;
Nagahari, Kenji;
Masuho, Yasuhiko;**Assignee:** Helix Research Institute
Research Association for Biotechnology
[News, Profiles, Stocks and More about this company](#)**Published / Filed:** 2003-03-19 / 2002-03-21**Application** EP2002000006586**Number:****IPC Code:** [C12N 15/12](#); [C07K 14/47](#); [C07K 16/18](#); [G01N 33/53](#); [C12N 15/11](#); [C12Q 1/68](#);**Priority Number:** 2001-09-14 [JP2001000328381](#)
2002-01-24 [US2002000350435P](#)**Abstract:**

Full-length cDNAs are provided. 1639 cDNA derived from human have been isolated. The full-length nucleotide sequences of the cDNA and amino acid sequences encoded by the nucleotide sequences have been determined. Because the cDNA of the present invention are full-length and contain the translation start site, they provide information useful for analyzing the functions of the polypeptide.

Attorney, Agent VOSSIUS & PARTNER ;
or Firm:**INPADOC** [Show legal status actions](#)**Get Now:** [Family Legal Status Report](#)

Legal Status:
 Designated Country: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
 Family: [Show 2 known family members](#)
 Description: [Expand full description](#)

+ [FIELD OF THE INVENTION](#)
 + [BACKGROUND OF THE INVENTION](#)
 + [SUMMARY OF THE INVENTION](#)
 + [BRIEF DESCRIPTION OF THE DRAWINGS](#)
 + [DETAILED DESCRIPTION OF THE INVENTION](#)
 + [Osteoporosis-related genes](#)
 + [Genes involved in neural cell differentiation](#)
 + [Cancer-related genes](#)
 + [EXAMPLE 1](#)
 + [Preparation of cDNA library by oligo-capping](#)
 + [\(1\) Extraction and purchase of mRNA](#)
 + [\(2\) Preparation of cDNA library](#)
 + [\(3\) Assessment of the 5'-end completeness of clones derived from the cDNA library prepared by oligo-capping](#)
 + [EXAMPLE 2](#)
 + [Sequencing analysis of cDNA ends and selection of full-length clones](#)
 + [EXAMPLE 3](#)
 + [Analysis of the full-length nucleotide sequences](#)
 + [EXAMPLE 4](#)
 + [Functional prediction by homology search](#)
 + [EXAMPLE 5](#)
 + [Search for signal sequence, transmembrane domain and other functional domains in the deduced amino acid sequences](#)
 + [EXAMPLE 6](#)
 + [Functional categorization based on the full-length nucleotide sequences](#)
 + [EXAMPLE 7](#)
 + [Expression frequency analysis in *silico*](#)
 + [Osteoporosis-related genes](#)
 + [Genes involved in neural cell differentiation](#)
 + [Cancer-related genes](#)
 + [EXAMPLE 8](#)
 + [Expression frequency analysis by PCR](#)
 + [Homology Search Result Data](#)

First Claim: [Show all claims](#)
 1. A polynucleotide selected from the group consisting of the following (a) to (g):

- (a). a polynucleotide comprising a protein-coding region of the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639;
- (b) a polynucleotide encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1640 to 3278;
- (c) a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of any one of SEQ ID NOs: 1640 to 3278, wherein, in said amino acid sequence, one or more amino acids have been substituted, deleted, inserted, and/or added, and wherein said nucleotide sequence encodes a polypeptide functionally

equivalent to a polypeptide comprising the selected amino acid sequence;

- (d) a polynucleotide hybridizing to a polynucleotide comprising the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639, wherein said nucleotide sequence encodes a polypeptide functionally equivalent to a polypeptide encoded by the selected nucleotide sequence;
- (e) a polynucleotide comprising a nucleotide sequence encoding a partial amino acid sequence of a polypeptide encoded by the polynucleotide according to any one of (a) to (d);
- (f) a polynucleotide comprising a nucleotide sequence having at least 70% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639; and
- (g) a polynucleotide comprising a nucleotide sequence having at least 90% identity to the nucleotide sequence of any one of SEQ ID NOs: 1 to 1639.

Other Abstract
Info:

None



Nominate this for the

Gallery...

© 1997-2003 Thomson Delphion

Research Subscriptions | Privacy Policy | Terms & Conditions | Site Map | Contact